Key result
Prophylactic pentoxifylline diminishes doxorubicin-induced cardiac biomarker alterations, oxidative stress, and inflammation in rats.
Why the study?
Does prophylactic pentoxifylline prevent doxorubicin-induced cardiotoxicity in rats?
Does prophylactic pentoxifylline prevent doxorubicin-induced cardiotoxicity in rats?
Prophylactic pentoxifylline abrogates doxorubicin-induced cardiotoxicity in a rat model by mitigating oxidative stress, inflammation, and apoptosis.
Answers are grounded in this paper and cite their sources.
May attenuate doxorubicin cardiotoxicity in rats; leaves open clinical translation and requires human trials.
Doxorubicin (DOX) possesses a broad-spectrum antineoplastic activity; however, its clinical application is impeded by cardiotoxicity. This study aimed to investigate the protective effect of pentoxifylline (PXF), which possesses antioxidant and anti-inflammatory properties against cardiotoxicity induced by a single high dose (15 mg/kg, i.p.) or multiple low doses (2.5 mg/kg, i.p., three times per week for 2 weeks) of DOX. At the end of the experimental period, the serum creatine kinase (CK)-MB and lactate dehydrogenase (LDH) activities were measured. The hearts were then removed for evaluating TNF-α, NO, malondialdehyde (MDA), and reduced glutathione (GSH) levels, superoxide dismutase (SOD) and catalase (CAT) activities, and the expression of iNOS, NF-κB, Fas ligand (FasL), and caspase-3. The administration of DOX in both dose regimens caused increases in serum CK-MB and LDH activities, in cardiac TNF-α, NO and MDA levels, as well as in the cardiac expression of iNOS, NF-κB, FasL and caspase-3, whereas it significantly reduced the cardiac GSH level, as well as SOD and CAT activities (P < 0.05). Prophylactic treatment of rats with PXF diminished DOX-induced alterations in theses parameters. Our results warrant the clinical use of PXF as an adjuvant therapy to abrogate cardiotoxicity of DOX and extend its clinical applications.
No takes yet. Share an insight, caveat, or question.
Elshazly et al. (2016) studied Doxorubicin-induced cardiotoxicity. Pentoxifylline vs. Doxorubicin alone was evaluated on Serum CK-MB and LDH activities, cardiac TNF-α, NO, MDA, GSH, SOD, CAT, iNOS, NF-κB, FasL, and caspase-3. Prophylactic treatment with pentoxifylline diminished doxorubicin-induced alterations in cardiac biomarkers, oxidative stress, and inflammatory parameters in rats.
Synapse has enriched 10 related papers. Consider them for comparative context: